Tag

• UGI USER
• Cobenfy FDAApproval HealthcareInnovation MedicalBreakthrough MentalHealthMatters MentalHealthSupport NewMedication PharmaNews SchizophreniaAwareness SchizophreniaTreatment
• 2
• 0

FDA Approval for Cobenfy Casts Light on Schizophrenia’s Wickedness

Relevance: GS – 3 : Science and Technology – developments. Why in the News? On September 26, the U.S. FDA approved Cobenfy for the treatment of schizophrenia. Cobenfy is notable for its novel mechanism of action, targeting cholinergic receptors instead of dopamine receptors. This makes Cobenfy the first antipsychotic that does not rely on dopamine …

Read More